What topics does this cannabis study cover?

This study covers research on: CBD, Epilepsy, Mental Health, Sleep, Neuroprotection.

Where was this research published?

Published in Epilepsy research on July 14, 2026.

CBD Epilepsy Mental Health Sleep Neuroprotection

CBD may improve more than seizures in hard-to-treat epilepsy

Q: What did this Review find?

A review of **32 studies involving 1,343 patients** found reported improvements in at least one nonseizure outcome after starting highly purified *CBD*.

A systematic review of highly purified cannabidiol in developmental and epileptic encephalopathies and complex treatment-resistant epilepsies: Nonseizure outcomes.

Epilepsy research • July 14, 2026 • Review • Highly Relevant

🤖

AI Summary

This systematic review examined whether highly purified cannabidiol (CBD) oral solution may help with outcomes beyond seizure control in people with developmental and epileptic encephalopathies and complex treatment-resistant epilepsies, excluding Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. The review included 32 studies involving 1,343 patients. Improvements were reported across areas such as cognition, communication, behavior, motor function, sleep, quality of life, and neuropsychiatric health.

The findings suggest that medically supervised CBD treatment may offer benefits beyond reducing seizures, including possible improvements in daily functioning and reduced reliance on other antiseizure medicines. Reported side effects were consistent with CBD’s established safety profile and were most often gastrointestinal, including diarrhea, vomiting, and reduced appetite. However, most studies were observational and had a moderate to high risk of bias, so the results are encouraging but require confirmation in more rigorous research. These findings apply to prescription, highly purified CBD—not cannabis products generally.

💡 Key Findings

A review of 32 studies involving 1,343 patients found reported improvements in at least one nonseizure outcome after starting highly purified CBD.

Good

65%

Improvements were reported in cognition, communication, behavior, motor function, sleep, quality of life, and neuropsychiatric function.

Good

60%

Reported adverse events were consistent with the known CBD safety profile and were commonly gastrointestinal, including diarrhea, vomiting, and decreased appetite.

High

80%

The evidence suggests possible benefits beyond seizure control, but most studies were observational and had a moderate to high risk of bias, highlighting the need for confirmatory trials.

High

90%

📄 Original Abstract

A plant-derived, highly purified cannabidiol (CBD) oral solution (Epidiolex® [US]/Epidyolex® [EU]) is approved for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC). Improvements in nonseizure outcomes including cognition and behavior have been reported in patients with epilepsy administered CBD. This systematic literature review (SLR) evaluated studies reporting changes in nonseizure outcomes after CBD initiation in patients with developmental and epileptic encephalopathies (DEEs) and complex treatment-resistant epilepsies (TREs) other than LGS, DS, and TSC. An SLR was conducted in March 2024 according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Embase, Medline, and Cochrane Central Register of Controlled Trials libraries were searched for studies on TREs, CBD, nonseizure outcomes, and adverse events (AEs). Results were narratively summarized. Thirty-two studies comprising 1343 patients were included. Thirty-one studies reported improvement in nonseizure outcomes in ≥ 1 patient, including neuropsychiatric function (n = 9/9 studies), cognitive function (n = 9/9), use of concomitant antiseizure medications (n = 7/8), communication (n = 7/7), behavior (n = 7/7), motor function (n = 6/6), healthcare utilization (n = 5/5), quality of life (n = 5/5), global change (n = 4/4), sleep (n = 2/2), and development (n = 2/2). Reported AEs were consistent with the known safety profile of CBD and most commonly gastrointestinal, including diarrhea (17-34%), vomiting (5-50%), and decreased appetite (7-20%). This SLR mainly identified observational studies with moderate to high bias risk. The available evidence suggests CBD may improve various nonseizure outcomes in patients with DEEs and complex TREs, while underscoring the need for rigorous confirmatory studies.

Paper Type

📚 Review

Publication

Journal: Epilepsy research
Published: July 14, 2026
PMID: 42520581
DOI: 10.1016/j.eplepsyres.2026.107873

Authors (4)

Debopam Samanta Child Neurology Section, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Lisa Moore-Ramdin Jazz Pharmaceuticals, UK Ltd., London, UK.
Marco Navetta Jazz Pharmaceuticals, Inc., Palo Alto, CA, USA.
Antonietta Coppola Epilepsy Centre, Department of Neuroscience, Reproductive Sciences and Odontostomatology, Federico II University, Naples, Italy. Electronic address: antonietta.coppola1@gmail.com.